Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 773 clinical trials
Flu-Bu-Mel Conditioning Regimen for Myeloid Disease

For patients with acute myeloid leukemia (AML) or myelodyspasia syndrome undergoing allo-HSCT, the conditioning regimen will be 5-day Fludarabine, 2-day Busulifan and 2-day melphalan

  • 0 views
  • 16 Feb, 2024
  • 2 locations
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults

The purpose of the CliniMACS TCR-Biotin System and CliniMACS CD19 is to improve the safety and efficacy of allogeneic HLA-partially matched related or unrelated donors HSCT when no matched donors are available, to treat malignant and nonmalignant disorders for which HSCT is the recommended best available therapy.

immunosuppression
cardiovascular disease
renal function
hla-drb1
direct bilirubin
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) with LentiGlobin BB305 Drug Product for SCD.

priapism
gene therapy
pediatric
analgesia
karnofsky performance status
  • 0 views
  • 16 Feb, 2024
  • 2 locations
Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag

Background Diamond-Blackfan anemia (DBA) is treated with steroids. But some people cannot take steroids, or steroids don t work. Other patients must get blood transfusions regularly which are time consuming and can have significant side effects. The drug eltrombopag can increase red blood cells. Researchers want to see if it …

bone marrow biopsy
blood transfusion
corticosteroids
bone marrow erythroid
electrocardiogram
  • 0 views
  • 16 Feb, 2024
  • 1 location
Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD

Therapy of severe intestinal graft-versus-host disease (GVHD) despite the introduction of novel target agents is associated with worse outcome compared to the other forms. Response to steroids is observed only in about 10% of patients. The most promising approaches are JAK inhibition and fecal microbiota transplantation. In this pilot study …

ruxolitinib
acute graft-versus-host disease
graft versus host disease
  • 0 views
  • 16 Feb, 2024
  • 1 location
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R or Chronic Myelomonocytic Leukemia-2 (CMML-2)

This is a Phase III multi-center, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to azacitidine in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who have an indication for treatment with azacitidine in first-line …

high risk myelodysplastic syndrome
myelodysplastic syndrome
chronic myelomonocytic leukemia
leukemia
stem cell transplantation
  • 0 views
  • 16 Feb, 2024
  • 23 locations
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Treatment options for older adults with Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS) are limited. Although stem cell transplantation remains one of the most effective treatments it is associated with severe side effects which have until recently prevented its use in older adults.

acute myeloid leukemia
leukemia
behavioral intervention
blood count
conditioning therapies
  • 0 views
  • 16 Feb, 2024
  • 1 location
T Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse

Safety and Effectiveness of Donor T Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

  • 0 views
  • 05 Aug, 2020
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL

As part of postremission consolidative therapy, the decision to proceed with hematopoietic stem cell transplantation is a recommendable regimen in ALL therapy. However, The recurrence rate is high after transplantation. Minimal Residual Disease (MRD) is an important factor affecting the effect of HSCT.

  • 0 views
  • 12 Jul, 2023
  • 2 locations
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia

This phase II trial studies how well total marrow and lymphoid irradiation works as a conditioning regimen before hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute leukemia. Total body irradiation can lower the relapse rate but has some fatal side effects such as irreversible damage to normal internal …

lymphoblastic leukemia
vincristine
preparative regimen
carbon monoxide diffusing capability test
hepatitis c
  • 0 views
  • 16 Feb, 2024
  • 1 location